Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates

Core Insights - Iovance Biotherapeutics reported approximately 30% quarterly revenue growth driven by increasing demand for Amtagvi, achieving full year 2025 revenue of $264 million, which met the annual guidance range of $250 million to $300 million [3][4] - The gross margin improved to 50% in the fourth quarter of 2025, reflecting operational improvements and cost optimization [4][3] - The company is well-positioned for future profitability as it advances its registrational trial in non-small cell lung cancer and continues to develop its TIL pipeline [3][4] Financial Performance - Fourth quarter 2025 total product revenue was approximately $87 million, a 30% increase from the previous quarter, with U.S. Amtagvi revenue of about $65 million and global Proleukin revenue of around $22 million [4] - Full year 2025 total product revenue reached approximately $264 million, including U.S. Amtagvi revenue of about $220 million and global Proleukin revenue of approximately $44 million [4] - The cash position as of December 31, 2025, was approximately $303 million, expected to fund operations into the third quarter of 2027 [4] Operational Highlights - The company has implemented operational excellence initiatives, including the internalization of all lifileucel manufacturing, which are expected to drive further improvements in operating expenses and gross margin in 2026 and 2027 [4] - A growing network of U.S. authorized treatment centers (ATCs) has expanded patient access, with community ATCs beginning to treat patients in late 2025 [4][6] - An oral presentation reported an overall objective response rate (ORR) of approximately 44% for Amtagvi, with a higher ORR of 52% after two or fewer prior lines of therapy, emphasizing the importance of early treatment [4][6] Regulatory and Pipeline Developments - The U.S. FDA granted Fast Track Designation for lifileucel in the treatment of advanced non-small cell lung cancer, with positive interim data indicating a potential best-in-class profile [5][6] - Iovance plans to support a supplemental Biologics License Application for U.S. accelerated approval with a potential launch in the second half of 2027 [5][6] - The company is also advancing multiple clinical trials across various solid tumor indications, including a registrational trial for advanced undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma [5][6]